Medication For Staph Infection

Delmont's Staphage Lysate

There is a way to end the cycle of frustrating and excessive expense when your antibiotic
therapy works short-term wonders, but results in chronic problems soon after treatment
is terminated. Delmont's Staphage Lysate (SPL) has been shown to be a highly effective
immunotherapeutic when used concurrently with or as a follow-up to antibiotics in the
treatment of idiopathic recurrent canine pyoderma.
Documented Efficacy
In addition to widespread use in veterinary practices, SPL's value has been recorded in
controlled studies. Significantly, use of SPL represents a proven way to avoid extended use
of antibiotics.
The Professional Solution
With SPL, your practice gains clients' appreciation for having controlled the dog's pruritic
lesions on a long-term basis. Clients also appreciate the saving in time and money
required by indefinite antibiotic regimens.

SPL Information
SPL is a highly effective bacterial antigen licensed for the treatment of idiopathic canine
pyoderma. It is the only staphylococcal product of its kind approved for canine use.
Our double blinded study demonstrated a 77% efficacy rate in pyoderma caused by
Staphylococcus intermedius.
The most important predictor of successful SPL therapy is the selection of appropriate
cases.
The dog should have a history of recurrent, idiopathic pyoderma.
Its disease should be responsive to antibiotics.
All underlying causes should be ruled out (i.e., demodicosis, flea allergy dermatitis,
food allergy and hypothyroidism).

Recurrent Staphylococcal Infections

A major concern of veterinary dermatologists has been the recalcitrant nature of recurrent
pyoderma. Too often - shortly upon the conclusion of an antibiotic treatment modality staphylococcal skin infection recurs.
Traditionally, three treatment programs are utilized by veterinary dermatologists: (1)
antibiotics; (2) benzyl peroxide shampoos for the elimination of the staph; and (3)
immune-therapy with products such as Staphylococcus Aureus Phage Lysate.
Immunostimulants which are frequently used to treat pyoderma have a common
mechanism of enhancing cellular immunity. Cellular immune mechanisms generally
involve the activation of phagocytes and the stimulation of T cells.

Immunological Research
Current immunological research studies indicate that one set of helper T cells designated
TH1 is important for providing cell-mediated resistance to infection while TH2 cells
provide a humoral response and suppress cell-mediated responses. These T cells produce
distinctly different regulatory cytokines with TH2 cells producing IL-4, IL-5, and IL-l0. 1L-4
has been reported to block IL-2 dependent proliferation of T cells and can block
macrophage nitric oxide generation, which is necessary for killing intracellular parasites.1

Human Clinical Study

Delmont Laboratories has recently sponsored a human clinical study on the use of
Staphage Lysate (SPL) to treat various staphylococcal infections, predominantly those
affecting the skin.
During therapy, the number of active peripheral blood phagocytes increased as the
symptoms decreased. A total of 99 patients were treated by six different physicians. The
conditions treated included impetigo, recurrent furunculosis, atopic eczema,
osteomyelitis, otitis media, and hidradenitis suppurativa.2
For example - in cases of staphylococcal impetigo - complete clearing of the infection
was observed after an 8 - 12 week period of treatment. These patients had a
substantial increase in the number of active peripheral phagocytes as measured by
uptake of Candida albicans. The course of therapy and the time required to show
improvement were similar to that found using Staphage Lysate (SPL) in cases of
canine pyoderma.

For more information please visit

http://www.delmont.com
Delmont Laboratories, Inc.
715 Harvard Avenue
PO Box 269, Swarthmore, PA 19081
email: splvet@delmont.com
Phone: (610) 543-3365